Table 2 Immune cell infiltration into breast tumours following PST

From: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

	TAXHER01 ( n =23)	Control ( n =46)	D ( n =23)	NT–NT ( n =23)	TAXHER01 vs control	D vs NT–NT
Antibodies location	Mean (s.d.) staining intensity score				P -value
CD20
Diffuse	1.61 (1.3)	1.10 (0.9)	1.09 (0.9)	1.04 (0.9)	0.0802	0.8272
Around	1.13 (1.5)	0.52 (1.2)	0.39 (1.0)	0.65 (1.3)	0.0598	0.4432
Inside	0.43 (0.9)	0.33 (0.9)	0.04 (0.1)	0.61 (1.2)	0.4013	0.0686
Foci	3.13 (1.2)	1.70 (1.5)	1.61 (1.4)	1.78 (1.7)	0.0005	0.8391
CD3
Diffuse	2.09 (1.4)	1.42 (1.0)	1.35 (0.9)	1.50 (1.1)	0.0386	0.7389
Around	1.52 (1.6)	0.82 (1.5)	0.70 (1.4)	0.95 (1.5)	0.0560	0.5014
Inside	0.65 (1.2)	0.47 (1.0)	0.39 (0.9)	0.55 (1.1)	0.4734	0.5014
Foci	2.87 (1.1)	1.64 (1.2)	1.43 (1.1)	1.86 (1.4)	0.0001	0.2116
CD4
Diffuse	1.04 (1.3)	0.91 (0.9)	0.91 (0.8)	0.91 (0.9)	0.7605	0.8776
Around	1.35 (1.7)	0.46 (1.0)	0.39 (1.0)	0.52 (1.1)	0.0270	0.5223
Inside	0.35 (0.7)	0.04 (0.2)	0.00 (0.0)	0.09 (0.3)	0.0209	0.1527
Foci	2.17 (1.3)	1.30 (1.3)	1.65 (1.2)	0.96 (1.3)	0.0107	0.0627
CD8
Diffuse	1.96 (1.5)	1.87 (0.9)	1.96 (0.9)	1.78 (1.0)	0.5670	0.4738
Around	1.56 (1.7)	0.76 (1.4)	0.52 (1.2)	1.00 (1.5)	0.0460	0.1997
Inside	1.22 (1.3)	0.78 (1.1)	0.65 (1.1)	0.91 (1.0)	0.1999	0.2454
Foci	2.39 (1.6)	1.50 (1.4)	1.43 (1.3)	1.56 (1.5)	0.0160	0.6410
CD68
Diffuse	1.91 (1.3)	2.30 (1.2)	2.43 (1.2)	2.17 (1.2)	0.3036	0.5172
Around	0.91 (1.6)	0.54 (1.3)	0.48 (1.3)	0.61 (1.3)	0.3594	0.5271
Inside	0.56 (1.0)	0.39 (0.8)	0.26 (0.7)	0.52 (0.8)	0.5676	0.1883
Foci	0.09 (0.4)	0.00 (0.0)	0.00 (0.0)	0.00 (0.0)	0.1573
PS100
Diffuse	1.70 (1.3)	1.59 (1.2)	1.48 (0.9)	1.70 (1.5)	0.7068	0.9540
Around	1.35 (1.6)	0.63 (1.3)	0.30 (0.9)	0.96 (1.5)	0.0557	0.1234
Inside	0.61 (1.3)	0.37 (0.9)	0.13 (0.6)	0.61 (1.1)	0.4579	0.0488
Foci	1.74 (1.7)	1.1 (1.4)	0.78 (1.2)	1.35 (1.6)	0.0691	0.2202
CD1a
Diffuse	1.61 (0.8)	1.83 (0.9)	1.74 (0.8)	1.91 (0.9)	0.3788	0.4385
Around	0.39 (0.7)	0.41 (1.0)	0.39 (1.0)	0.43 (1.0)	0.5556	0.5378
Inside	0.26 (0.5)	0.28 (0.9)	0.17 (0.7)	0.39 (1.0)	0.3180	0.5968
Foci	0.00 (0.0)	0.00 (0.0)	0.00 (0.0)	0.00 (0.0)
HLA-DR
Diffuse	2.09 (1.0)	2.33 (1.0)	2.26 (0.8)	2.39 (1.1)	0.5370	0.4624
Around	1.70 (1.7)	1.04 (1.5)	0.83 (1.5)	1.26 (1.5)	0.1151	0.2308
Inside	0.91 (1.2)	0.72 (1.0)	0.39 (0.8)	1.04 (1.1)	0.5778	0.0258
Foci	2.30 (1.1)	1.54 (1.3)	1.70 (1.3)	1.39 (1.3)	0.0335	0.4649
CD56 ^a
Diffuse	0.83 (1.0)	0.74 (0.8)	0.87 (0.8)	0.61 (0.8)	1.0000	0.2125
Around	1.00 (1.5)	0.57 (1.1)	0.43 (1.0)	0.70 (1.2)	0.2468^a	0.3175
Inside	0.30 (0.7)	0.11 (0.4)	0.09 (0.4)	0.13 (0.3)	0.2520^a	0.3336
Foci	0.26 (0.7)	0.28 (0.8)	0.26 (0.9)	0.30 (0.7)	0.9739	0.4756
NK1
Diffuse	1.45 (1.4)	1.20 (0.9)	1.39 (0.8)	1.00 (0.9)	0.5864	0.1349
Around	1.64 (1.6)	0.41 (1.0)	0.43 (1.1)	0.39 (1.0)	0.0003	0.7919
Inside	0.82 (1.3)	0.30 (0.8)	0.17 (0.7)	0.43 (1.0)	0.0438	0.2251
Foci	2.01 (1.4)	0.74 (1.1)	0.83 (1.1)	0.65 (1.1)	0.0003	0.4678
TiA1
Diffuse	1.13 (1.3)	1.30 (1.0)	1.30 (0.9)	1.30 (1.1)	0.4411	0.9816
Around	1.43 (1.7)	0.85 (1.5)	0.61 (1.4)	1.1 (1.6)	0.1982	0.3113
Inside	0.65 (1.0)	0.26 (0.8)	0.17 (0.7)	0.35 (0.9)	0.0370	0.3878
Foci	1.00 (1.0)	0.54 (1.0)	0.65 (1.2)	0.43 (0.8)	0.2181	0.5759
Granzyme B
Diffuse	0.26 (0.7)	0.26 (0.4)	0.30 (0.5)	0.22 (0.4)	0.4870	0.5066
Around	0.83 (1.3)	0.28 (0.9)	0.22 (0.9)	0.35 (0.9)	0.0324	0.4087
Inside	0.22 (0.7)	0.07 (0.3)	0.13 (0.5)	0.00 (0.0)	0.1926	0.1528
Foci	0.52 (0.8)	0.33 (0.7)	0.13 (0.3)	0.52 (0.9)	0.2571	0.1126

NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D, docetaxel-based PST.
For diffuse/around/inside/foci, scores range from 0 to 4.
^aStaining with CD56 was less intense and difficult to quantify.
Significant if P<0.05. Bold values signify their importance in the results and the discussion.

Back to article page

Table 2 Immune cell infiltration into breast tumours following PST

Search

Quick links